Journal: Molecular Therapy Oncology

Article Title: AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation

doi: 10.1016/j.omton.2026.201216

Figure Lengend Snippet: Differential transduction of human GBM cell lines with AAV vector serotypes (A) Representative images of U-87 MG and patient-derived cell lines transduced with AAV1, 2, 1/2, 6, and 6.2 expressing eGFP and pBS control-treated control. Green, GFP expression; magenta, EdU staining; blue, Hoechst staining. Scale bars, 100 μm. (B) Quantitation of the transduction efficiency for all serotypes in each cell line as determined by GFP expression. All data presented as mean (SD), n = 3 biological replicates.

Article Snippet: The commercial human GBM cell line U-87 MG (ATCC) was plated at 5,000 cells per well in Eagle’s minimal essential medium (EMEM) (ATCC, 30–2003) supplemented with 10% FBS (Gibco, 10091148) and Penicillin-Streptomycin-Glutamine (Gibco, 10378016).

Techniques: Transduction, Plasmid Preparation, Derivative Assay, Expressing, Control, Staining, Quantitation Assay

Journal: Molecular Therapy Oncology

Article Title: AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation

doi: 10.1016/j.omton.2026.201216

Figure Lengend Snippet: AAV transduced CD44-positive cell populations with greater efficiency (A) Transduction efficiency of AAV1, 2, 1/2, 6, and 6.2 in CD44-positive and -negative cell populations. Two-way ANOVA showed no significant interaction between the effects of AAV serotype and CD44 expression on transduction efficiency in all cell lines. There was a significant main effect of CD44 expression in U-87 MG ( p = 0.007), case 1 ( p = 0.0003), and case 4 ( p = 0.010) but no statistical significance was found following Sidak’s multiple comparisons test. (B) CD44 expression in human GBM cell lines following AAV treatment. (C) Proliferation of the CD44-positive cell population normalized to values from NTC-treated control. Treatments were compared against their respective pBS-treated control. All data presented as mean (SD), n = 3 biological replicates. Statistical significance is shown as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: The commercial human GBM cell line U-87 MG (ATCC) was plated at 5,000 cells per well in Eagle’s minimal essential medium (EMEM) (ATCC, 30–2003) supplemented with 10% FBS (Gibco, 10091148) and Penicillin-Streptomycin-Glutamine (Gibco, 10378016).

Techniques: Transduction, Expressing, Control

Journal: Molecular Therapy Oncology

Article Title: AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation

doi: 10.1016/j.omton.2026.201216

Figure Lengend Snippet: Reductions in cell number and proliferation following AAV treatment persisted in the absence of transgene expression (A) Representative images of U-87 MG, cases 2 and 5 transduced with AAV expressing eGFP or no transgene, along with their respective pBS controls. Green, GFP expression; magenta, EdU staining; blue, Hoechst staining. Scale bars, 100 μm. (B) Total cell number and (C) cell proliferation in the 24 h prior to fixation, normalized to values from NTC-treated control. Treatments were compared against their respective pBS-treated control. All data presented as mean (SD), n = 3 biological replicates. Statistical significance is shown as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: The commercial human GBM cell line U-87 MG (ATCC) was plated at 5,000 cells per well in Eagle’s minimal essential medium (EMEM) (ATCC, 30–2003) supplemented with 10% FBS (Gibco, 10091148) and Penicillin-Streptomycin-Glutamine (Gibco, 10378016).

Techniques: Expressing, Transduction, Staining, Control

Journal: Molecular Therapy Oncology

Article Title: AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation

doi: 10.1016/j.omton.2026.201216

Figure Lengend Snippet: AAV treatment induced cell-cycle arrest at G1 in cases 2 and 5 but not U-87 MG (A) Cumulative cytotoxicity was evaluated by LDH release assay 4 days following AAV treatment, normalized to the maximal LDH release from the Triton X-100 control. No statistical significance was detected. (B) Percentage of cells in each cell cycle phase (G0/G1, S, and G2/M) were quantified via DNA content profiling (see also ). All data presented as mean (SD), n = 3 biological replicates. Treatments were compared against their respective pBS-treated control. Statistical significance is shown as G0/G1 phases: ∗∗∗∗ p < 0.0001; S phase: † p < 0.05; G2/M phases: # p < 0.05, ### p < 0.001.

Article Snippet: The commercial human GBM cell line U-87 MG (ATCC) was plated at 5,000 cells per well in Eagle’s minimal essential medium (EMEM) (ATCC, 30–2003) supplemented with 10% FBS (Gibco, 10091148) and Penicillin-Streptomycin-Glutamine (Gibco, 10378016).

Techniques: Lactate Dehydrogenase Assay, Control

Journal: Molecular Therapy Oncology

Article Title: CBX6 and CA9 as predictive indicators and therapeutic targets in GBM

doi: 10.1016/j.omton.2026.201159

Figure Lengend Snippet: Hypoxia impacts gene expression and signaling pathways in GBM cells (A) Hypoxia-responsive pathways were identified using Partek Flow software under double filter MI50 and fold change >+1.5 criteria. (B) Expression of candidate genes in PBT030 cells following 48-h hypoxia exposure compared to cells under normoxic conditions. (C) Expression of candidate genes in U-87 MG cells after 48 h of hypoxia compared to cells maintained under normoxic conditions. Representative bar graphs are derived from at least two independent experiments, with 28S used as the reference gene for all experiments.

Article Snippet: U-251 MG and U-87 MG cell lines were purchased from the American Type Culture Collection (ATCC).

Techniques: Gene Expression, Protein-Protein interactions, Software, Expressing, Derivative Assay